Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal by Munera-Campos, Mónica et al.
17/3/2021 Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292470/?report=printable 1/5




Nivolumab-Induced Bullous Pemphigoid Managed without Drug
Withdrawal
Mónica Munera-Campos, Adrià Plana-Pla, Noelia Rivera, Aram Boada, and Carlos Ferrándiz
From the Department of Dermatology, Germans Trias I Pujol University Hospital, Universitat Autònoma De
Barcelona, Badalona, Spain
Address for correspondence: Dr. Mónica Munera-Campos, Department of Dermatology, Germans Trias I Pujol
University Hospital, Universitat Autònoma De Barcelona, Carretera De Canyet, S/N, 08916 Badalona, Barcelona,
Spain. E-mail: monicamunera@hotmail.com
Received 2018 Jul; Accepted 2018 Sep.
Copyright : © 2020 Indian Journal of Dermatology
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-
commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Abstract
The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual
immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid
secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complete
response to clobetasol ointment alone. The autoimmune blistering disease was successfully treated without
oral corticosteroids, and the anti-PD-1 agent could be maintained without recurrence of the skin lesions.
Topical therapy remains a good option in selected, mild-to-moderate cases of induced bullous pemphigoid.
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Introduction
Immune checkpoint inhibitors, such as nivolumab, have revolutionized the treatment of some metastatic
tumors, such as melanoma or lung cancer. However, up to 40% of patients may develop immune-related
adverse events affecting the skin.[1] Autoimmune blistering diseases have infrequently been described.
We report a case of bullous pemphigoid appeared shortly after the second dose of nivolumab and managed
without drug withdrawal.
Case Report
A 62-year-old man presented at our department with a 1-month history of a generalized and pruritic
eruption. The patient had no previous history of autoimmune or inflammatory skin conditions. Medical
history was significant for metastatic renal carcinoma previously treated with sunitinib and everolimus,
none of which were effective. Treatment with nivolumab (3 mg/kg intravenously every 2 weeks), started 1
month before the eruption, achieved a good response of his oncologic disease.
On examination, the skin showed numerous hemorrhagic crusted papules and plaques especially affecting
the trunk [Figure 1a], and two active bullous lesions were present on the dorsum of his right arm [
Figure 1b]. Skin biopsy of an intact lesion showed a subepidermal blister [Figure 2a] with a dermal
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lymphocytic infiltrate with numerous eosinophils [Figure 2b]. A linear deposition of C3 (+++) and
immunoglobulin G (++) at the dermo-epidermal junction was shown on direct immunofluorescence [
Figure 2c]. The enzyme-linked immunosorbent assay for BP180 autoantibody was positive, with a
negative BP230. These changes were consistent with the clinical impression of bullous pemphigoid.
As the patient had shown good response and the adverse event was tolerable, nivolumab was maintained,
and treatment for bullous pemphigoid was started with clobetasol ointment followed by a progressive
reduction to a weekly maintenance therapy. The response was complete with topical steroid. No relapse
was observed with the following nivolumab administrations.
Discussion
Nivolumab is a monoclonal antibody that specifically targets the programmed cell death receptor-1 (PD-1),
thus improving the T-cell-mediated antitumor response. Dermatologic toxicities are among the more
frequent adverse events of these drugs.[2]
To our knowledge, more than 20 cases of bullous pemphigoid in patients receiving anti-PD-1 agents have
been reported, 10 of them induced by nivolumab, 12 by pembrolizumab, and 1 by durvalumab.
[1,2,3,4,5,6,7] The association of bullous pemphigoid with cytotoxic T-lymphocyte-associated protein-4
(CTLA-4) inhibitors, such as ipilimumab remains controversial, as reported cases appeared in association
with anti-PD-1 therapy, but no cases have been reported with CTLA-4 inhibitors alone.[2] While bullous
pemphigoid has mostly been described in the setting of immunotherapy for metastatic melanoma, lung
cancer, and urothelial carcinoma,[2] there is only one other case reported in a patient with metastatic renal
carcinoma, which required drug withdrawal.[8]
Although pathogenesis is not fully understood, it is hypothesized that anti-PD-1/programmed cell death
ligand-1 (PD-L1) blockade may result in a loss of tolerance and the development of T-cells against BP180.
Moreover, a humoral response may result from the activation of B-cell germinal center secondary to an
interaction between PD-1/PD-L1 expressing B-cells and PD-1+ follicular helper cells.[9]
A potential association between bullous pemphigoid with an improved survival in patients receiving anti-
PD-1 inhibitors has been suggested. However, response rates in these patients (41.7%) seem to be similar
to that reported in the literature, and induced-bullous pemphigoid does not seem to be a marker of a better
response.[2,4]
The persistence and the severity of bullous pemphigoid lesions led to therapy discontinuation in previous
reports.[2,4,7,9] In general, treatment includes topical and oral steroids,[2] but other therapies, including
omalizumab[4] and rituximab,[6] have also been used. In our case, nivolumab could be maintained as
clobetasol ointment alone achieved a complete response.
Conclusion
As new indications of anti-PD-1 therapies in other neoplasms arise, an increase is expected in the number
of immune-related adverse events, including autoimmune skin diseases. Thus, awareness and close
monitoring of dermatological toxicities is crucial to ensure an adequate management. Immunotherapy
withdrawal is not always mandatory and should be individualized. Topical therapy remains a good option
in selected, mild-to-moderate cases.
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Figure 1
Clinical features. Crusted papules and plaques on the trunk (a) and active bulla on the right arm (b)
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Figure 2
Histopathological and immunological features. Histopathological features include a subepidermal blister (H and
E, ×40) (a) with eosinophil infiltration (H and E, ×200) (b). Direct immunofluorescence for C3 shown linear
deposition at the dermal-epidermal junction (Immunofluorescence stain, ×100) (c)
Articles from Indian Journal of Dermatology are provided here courtesy of Wolters Kluwer -- Medknow
Publications
